ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on December 15, 2020. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Ann Arbor, Michigan. Its common stock (NDRA) and warrants (NDRAW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate action regarding a sales agreement.
Material Changes
The Company terminated its At-The-Market Issuance Sales Agreement (the "ATM Agreement") with Ascendiant Capital Markets, LLC, effective immediately on December 15, 2020. The agreement, originally entered into on September 25, 2020, allowed the Company to sell up to $6.8 million of common stock through an "at-the-market" offering.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the termination of the sales agreement. There are no unusual items reported.
Key Facts for Investor Verification
- The ATM Agreement allowing for up to $6.8 million in equity sales was terminated on December 15, 2020.
- The termination was effective immediately upon written notice to the sales agent, Ascendiant Capital Markets, LLC.
- The Company remains an emerging growth company.
- Investors should review the original ATM Agreement filed as Exhibit 1.1 to the September 25, 2020, Form 8-K for full terms.